MNPR - Why Is Cancer Drug Focused Monopar Therapeutics Stock Trading Higher On Tuesday? | Benzinga
Monopar Therapeutics Inc (NASDAQ:MNPR) shares jumped over 100% during the trading on Tuesday on a strong volume session volume of 3.94 million, compared to an average volume of 159.7K, as per the data from Benzinga Pro.
Tuesday, Monopar Therapeutics received Human Research Ethics Committee (HREC) clearance in Australia to commence a Phase 1 dosimetry trial of its radiopharmaceutical MNPR-101-Zr.
The 12-subject trial will enroll patients with advanced cancers and utilize positron emission tomography (PET) imaging to assess tumor ...